Papers

9

Total Citations

240

H-Index

7

About

Dr. Hongjing Jiang is a leading surgical oncologist specializing in the treatment of esophageal squamous cell carcinoma (ESCC), with a particular focus on advancing minimally invasive surgical techniques and multimodal therapy. Her major contributions center on refining robot-assisted minimally invasive esophagectomy (RAMIE), especially the technically demanding lymph node dissection around the left recurrent laryngeal nerve—a procedure critical for improving patient outcomes. Dr. Jiang has demonstrated through multiple studies (with papers cited 38, 33, and 26 times) that RAMIE offers superior short-term outcomes compared to video-assisted and open approaches. She also led the international consensus statement on RAMIE, establishing global standards for the procedure. Her work extends into neoadjuvant chemoimmunotherapy, where her Keystone-001 trial (62 citations) investigates pembrolizumab combined with paclitaxel and cisplatin as a preoperative strategy for stage III ESCC. With over 240 total citations, Dr. Jiang’s research is shaping the future of esophageal cancer surgery, making her a pivotal figure in the field.

Research Focus

Key Achievements

7
H-Index
9
Papers
240
Total Citations
27
Avg Citations/Paper
🏆 Most Cited Paper
Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001)
62 citations · 2022
📈 Most Prolific Year: 2020 (4 Papers)
🤝 Key Collaborators: 62
🏛 Institutions: Tianjin Medical University Cancer Institute and Hospital, Sun Yat-sen University

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago